Iacopo Baussano (France)
International Agency for Research on Cancer Infection and Cancer Epidemiology Group
Presenter of 1 Presentation
PREDICTING COHORT-SPECIFIC CERVICAL CANCER INCIDENCE FROM POPULATION-BASED HPV PREVALENCE SURVEYS: A WORLDWIDE STUDY (ID 531)
Session Time
12:35 - 13:50
Session Type
Public Health Oral Session
Lecture Time
13:35 - 13:47
[{"name":"PREDICTING COHORT-SPECIFIC CERVICAL CANCER INCIDENCE FROM POPULATION-BASED HPV PREVALENCE SURVEYS: A WORLDWIDE STUDY \u003Csmall\u003E(ID 531)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":531,"presentation":"PREDICTING COHORT-SPECIFIC CERVICAL CANCER INCIDENCE FROM POPULATION-BASED HPV PREVALENCE SURVEYS: A WORLDWIDE STUDY \u003Csmall\u003E(ID 531)\u003C\/small\u003E","session":"Oral Session 16: EPIDEMIOLOGY II. Burden, natural history and risk factors\u00a0","presenter":"Iacopo Baussano (France)","photo":""},"playlist":[{"name":"PREDICTING COHORT-SPECIFIC CERVICAL CANCER INCIDENCE FROM POPULATION-BASED HPV PREVALENCE SURVEYS: A","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/59\/Iacopo Baussano - IPVC20 - PRESENTATION 531.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/59\/Iacopo Baussano - IPVC20 - PRESENTATION 531.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/59\/7BA30EE1.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/59\/Iacopo Baussano - IPVC20 - PRESENTATION 531.vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"8E22UU0aa"}
[session]
[presentation]
[presenter]
Moderator of 1 Session
Session Type
Public Health Oral Session
Session Time
09:00 - 10:00
[{"name":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER \u003Csmall\u003E(ID 412)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":412,"presentation":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER \u003Csmall\u003E(ID 412)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"P\u00e4r Spar\u00e9n (Sweden)","photo":""},"playlist":[{"name":"EFFECTIVENESS OF HPV VACCINATION AGAINST INVASIVE CERVICAL CANCER","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/1269F6D7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/412 Par Sparen.vtt"}]},{"name":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN \u003Csmall\u003E(ID 1078)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1078,"presentation":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN \u003Csmall\u003E(ID 1078)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Mona Saraiya (United States of America)","photo":""},"playlist":[{"name":"IMPACT OF HPV VACCINATION ON CERVICAL CANCER INCIDENCE IN YOUNG US WOMEN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/6899418.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/Mona S 1087.vtt"}]},{"name":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA AFTER 10 YEARS OF THE HPV VACCINATION PROGRAM \u003Csmall\u003E(ID 660)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":660,"presentation":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA AFTER 10 YEARS OF THE HPV VACCINATION PROGRAM \u003Csmall\u003E(ID 660)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Laurie Smith (Canada)","photo":""},"playlist":[{"name":"POPULATION-BASED EVALUATION OF TYPE-SPECIFIC HPV PREVALENCE AMONG WOMEN IN BRITISH COLUMBIA, CANADA ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/963A7278.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P660_S1180_Laurie Smith.vtt"}]},{"name":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE CERVICAL PRECANCER INCIDENCE RATES, UNITED STATES, 2008-2015 \u003Csmall\u003E(ID 175)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":175,"presentation":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE CERVICAL PRECANCER INCIDENCE RATES, UNITED STATES, 2008-2015 \u003Csmall\u003E(ID 175)\u003C\/small\u003E","session":"Oral Session 15: VACCINATION V. Impact and effectiveness","presenter":"Julia W. Gargano (United States of America)","photo":""},"playlist":[{"name":"VACCINE IMPACT, CROSS-PROTECTION, AND TYPE REPLACEMENT EVALUATED WITH TYPE-SPECIFIC HPV-ATTRIBUTABLE","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/D457A73F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/54\/P175_S1180_VACCINE IMPACT.vtt"}]}]
{"type":2,"code":"7E32UU0W"}
[session]
[presentation]
[presenter]
